< Terug naar vorige pagina


Aducanumab: a new phase in therapeutic development for Alzheimer's disease?

Tijdschriftbijdrage - Tijdschriftartikel

On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.
Tijdschrift: EMBO Molecular Medicine
ISSN: 1757-4676
Issue: 8
Volume: 13
Aantal pagina's: 3
Jaar van publicatie:2021
Trefwoorden:Experimentele geneeskunde